4.5 Article

Baculovirus vector as an avian influenza vaccine: Hemagglutinin expression and presentation augment the vaccine immunogenicity

Journal

JOURNAL OF BIOTECHNOLOGY
Volume 164, Issue 1, Pages 143-150

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jbiotec.2012.12.013

Keywords

Baculovirus; Avian influenza; Vaccine; Antigen presentation; MHC class I; Vector vaccine

Funding

  1. National Tsing Hua University (Toward World-Class University Project) [100N2050E1, 99N2544E1]
  2. Ministry of Health [DOH99-TD-I-111-TM022]
  3. National Science Council, Taiwan [NSC100-2622-E-007-003-CC2, NSC99-2622-E-007-012-CC2, NSC 98-2221-E-007-047-MY3]

Ask authors/readers for more resources

Baculovirus simultaneously displaying and expressing the avian influenza virus (AIV) hemagglutinin (HA) protein can induce potent anti-HA humoral and cellular immune responses. Based on the hypothesis that improving the antigen expression and presentation can further boost the AIV vaccine efficacies, we first constructed a baculoviral vector (Bac-HAW) with HA gene fused with the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) near its 3 end and expressed under the control of the hybrid CAG promoter. The WPRE fusion improved the HA expression and augmented the humoral and Th1 cellular immune responses after intramuscular administration into BALB/c mice. With Bac-HAW as the backbone, we next constructed Bac-HAMW which harbored the HA gene flanked with the signal sequence (MHCIss) and trafficking domain (MITD) of MHC class I molecule. In comparison with Bac-HAW, Bac-HAMW ameliorated the HA peptide presentation, significantly elevated the HA-specific humoral response (total IgG, IgG2a and hemagglutination inhibition titers) and favorably boosted the Th1 and IFN-gamma(+)/CD8(+) T cell responses without extraneous adjuvants. These data collectively confirmed that enhancement of antigen expression and presentation by combining the WPRE and MHCIss/MITD fusion canpotentiate the immunogenicity of the baculovirus-based vaccine, and implicates the potential of Bac-HAMW as an appealing AIV vaccine. (C) 2013 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available